drugset / Trial / NCT04761601
First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-01-097 in patients with advanced solid tumors.
Timeline
- Start
- 2021-03-03
- Primary completion
- 2024-02-19
- Completion
- 2024-02-29
Outcome
Outcome not reported
Stopped (Business): “Stopped for strategic business reasons. The decision to stop the study was not connected to any safety concerns, or new risk associated with the study product, intervention, or procedures.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UCT-01-097 | Unknown | — | Oral |
| Background | Gemcitabine | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | — |